IVAN DANKANICH: Open Payments
NPI 1295182269 · PORT CHARLOTTE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$481 in 28 payments from 10 companies in 2025. Trend: 2023 $298 · 2024 $367 · 2025 $481
Food & beverage: $481
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 10 | $145 |
| Amgen Inc. | 5 | $79 |
| Lilly USA, LLC | 4 | $73 |
| ABBVIE INC. | 2 | $48 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 1 | $27 |
| Corcept Therapeutics | 1 | $23 |
| PFIZER INC. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: Ozempic, OTEZLA, MOUNJARO, VRAYLAR, NEXLETOL, Veozah, Korlym, ZEPBOUND.
Industry payments across FL — which companies pay providers there.
